These ICD-10-CM codes may also be used for casefinding.  The detailed casefinding list contains each individual reportable code. ICD-10-CM Supplemental casefinding lists follow. Many of these codes are for diseases associated with cancer or represent neoplasm-related secondary conditions.   Experience among the SEER registries has proven that using the supplementary list significantly improves casefinding outcomes for benign brain and CNS tumors, hematopoietic and lymphoid neoplasms, and other reportable diseases.  It is recommended that each registry screen cases using the supplementary list as time permits.  

SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/2021-09/30/2022)

ICD-10-CM Code

Explanation of Code

B20

Human immunodeficiency virus [HIV] disease with other diseases

B97.33, B97.34,

B97.35

Human T-cell lymphotrophic virus, (type I [HTLV-1], type II [HTLV-II], type 2 [HIV

2]) as the cause of diseases classified elsewhere

B97.7

Papillomavirus as the cause of diseases classified elsewhere

C44.01, C44.02

Basal/squamous cell carcinoma of skin of lip

C44.11-, C44.12-

Basal/squamous cell carcinoma of skin of eyelid

C44.21-, C44.22-

Basal/squamous cell carcinoma of skin of ear and external auricular canal

C44.31-, C44.32-

Basal/squamous cell carcinoma of skin of other and unspecified parts of face

C44.41, C44.42

Basal/squamous cell carcinoma of skin of scalp and neck

C44.51-, C44.52-

Basal/squamous cell carcinoma of skin of trunk

C44.61-, C44.62-

Basal/squamous cell carcinoma of skin of upper limb, including shoulder

C44.71-, C44.72-

Basal/squamous cell carcinoma of skin of lower limb, including hip

C44.81, C44.82

Basal/squamous cell carcinoma of skin of overlapping sites of skin

C44.91, C44.92

Basal/squamous cell carcinoma of skin of unspecified sites of skin

D06.-

Carcinoma in situ of the cervix

D10.- - D31.-, D34, D35.0, D35.1, D35.5-,D35.9, D36.-

Benign neoplasms (see "must collect" list for reportable benign neoplasms) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors

Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.

D37. _ - D41. _

Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior)

Note: Screen for incorrectly coded malignancies or reportable by agreement

tumors

D44.0 - D44.2, D44.6-D44.9

Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5)

Note: Screen for incorrectly coded malignancies or reportable by agreement tumors

D47.01

Cutaneous mastocytosis (9740/1)

D47.09

Other mast cell neoplasms of uncertain behavior

D47.2

Monoclonal gammopathy

Note: Screen for incorrectly coded Waldenstrom’s macroglobulinemia

D47.Z2

Castleman disease

D48.-

Neoplasm of uncertain behavior of other and unspecified sites

D49.0 - D49.9

Neoplasm of unspecified behavior (except for D49.6 and D49.7)

D61.1

Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy”)

ICD-10-CM Coding instruction note: Use additional code for adverse effect, if

applicable, to identify drug

D61.810

Antineoplastic chemotherapy induced pancytopenia

D61.82

Myelophthisis

ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _)

D63.0

Anemia in neoplastic disease

ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)

D64.81

Anemia due to antineoplastic chemotherapy

D69.49, D69.59,

D69.6

Other thrombocytopenia

Note: Screen for incorrectly coded thrombocythemia

D70.1

Agranulocytosis secondary to cancer chemotherapy

ICD-10-CM Coding instruction: code also underlying neoplasm

D75.81

Myelofibrosis (note: this is not primary myelofibrosis [9961/3]

ICD-10-CM Coding instruction note:     Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _)

D76.-

Other specified diseases with participation of lymphoreticular and

reticulohistiocytic tissue

D89.0, D89.1

Other disorders involving the immune mechanism, not elsewhere classified

Note: Review for miscodes

D89.4-

Mast cell activation syndrome and related disorders

E08

Diabetes mellitus due to underlying condition

ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96)

E31.2-

Multiple endocrine neoplasia [MEN] syndromes

ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes

E34.0

Carcinoid syndrome

ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor

E83.52

Hypercalcemia

E88.09

Other disorders of plasma-protein metabolism, not elsewhere classified

E88.3

Tumor lysis syndrome (following antineoplastic chemotherapy)

G13.0

Paraneoplastic neuromyopathy and neuropathy

ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)

G13.1

Other systemic atrophy primarily affecting central nervous system in neoplastic disease

ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)

G32.8-

Other specified degenerative disorders of nervous system in diseases classified elsewhere

ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49)

G53

Cranial nerve disorders in diseases classified elsewhere

Note: Code first underlying neoplasm (C00-D49)

G55

Nerve root and plexus compressions in diseases classified elsewhere

ICD-10-CM Coding instruction note: code also underlying disease, such as neoplasm (C00-D49)

G63

Polyneuropathy in diseases classified elsewhere

ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49)

G73.1

Lambert-Eaton syndrome in neoplastic disease

ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)

G89.3

Neoplasm related pain (acute)(chronic)

G99.2

Myelopathy in diseases classified elsewhere

ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49)

H47.42

Disorders of optic chiasm in (due to) neoplasm

ICD-10-CM Coding instruction: Code also underlying condition

H47.52-

Disorders of visual pathways in (due to) neoplasm

ICD-10-CM Coding instruction: Code also underlying condition

H47.63-

Disorders of visual cortex in (due to) neoplasm

ICD-10-CM Coding instruction: Code also underlying condition

J34.81

Nasal mucositis (ulcerative)

J91.0

Malignant pleural effusion

ICD-10-CM Coding instruction: Code first underlying neoplasm

J93.12

Secondary spontaneous pneumothorax

ICD-10-CM Coding instruction: Code first underlying condition, such as: Malignant neoplasm of bronchus and lung (C34._) Secondary malignant

neoplasm of lung (C78.0_)

K12.31

Oral mucositis (ulcerative) due to antineoplastic therapy

K12.33

Oral mucositis (ulcerative) due to radiation

K22.711

Barrett's esophagus with high grade dysplasia

K62.7

Radiation proctitis

K62.82

Dysplasia of anus (AIN I and AIN II)

K92.81

Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)

L10.81

Paraneoplastic pemphigus

M31.11

Hematopoietic stem cell transplantation-associated thrombotic microangioplasty

Note: Effective 10/1/2021

M36.0

Dermato(poly)myositis in neoplastic disease

ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)

M36.1

Arthropathy in neoplastic disease

ICD-10-CM Coding instruction: Code first underlying neoplasm, such as: Leukemia

(C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0)

M84.5-

Pathologic fracture in neoplastic disease

ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49)

M90.6-

Osteitis deformans in neoplastic disease

ICD-10-CM Coding instruction: Code first the neoplasm (C40._, C41._)

N42.3

Dysplasia of prostate (PIN I and PIN II)

N52.35

Erectile dysfunction following radiation therapy

N52.36

Erectile dysfunction following interstitial seed therapy

N76.81

Mucositis (ulcerative) of vagina and vulva

N87.-

Dysplasia of cervix uteri (CIN I and CIN II)

N89.0, N89.1, N89.3

Vaginal dysplasia (VIN I and VIN II)

N90.0, N90.1, N90.3

Vulvar dysplasia (VAIN I and VAIN II)

O01.-

Hydatidiform mole Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3, ) malignancy code in the C00- C97 range

O9A.1-

Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96) ICD-10-CM Coding instruction: Use additional code to identify neoplasm

P04.11

Newborn affected by maternal antineoplastic chemotherapy

P04.12

Newborn affected by maternal cytotoxic drugs

Q85.0-

Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable

R18.0

Malignant ascites ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56. _), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)

R53.0

Neoplastic (malignant) related fatigue ICD-10-CM Coding instruction: Code first associated neoplasm

R59.-

Enlarged lymph nodes

R85.6-

Abnormal findings on cytological and histological examination of digestive organs Note: see "must collect" list for R85.614

R87.61-, R87.62-

Abnormal findings on cytological/histological examination of female genital organs Note: see "must collect" list for R87.614 and R87.624

R92.-

Abnormal findings on diagnostic imaging of breast

R97.-

Abnormal tumor markers

T38.6-

Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified

T38.8-, T38.9-

Poisoning by hormones and their synthetic substitutes

T45.1-

Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs

T45.8-, T45.9-

Poisoning by primary systemic and hematological agent, unspecified

T66

Unspecified effects of radiation

T80.1

Vascular complications following infusion, transfusion and therapeutic injection

T80.2-

Infections following infusion, transfusion and therapeutic injection

T80.810

Extravasation of vesicant antineoplastic chemotherapy

T80.818

Extravasation of other vesicant agent

T80.82

Complication of immune effector cellular therapy Complication of chimeric antigen receptor (CAR-T) cell therapy

T86.0

Complications of bone marrow transplant ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)

Y63.2

Overdose of radiation given during therapy

Y84.2

Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Z03.89

Encounter for observation for other suspected diseases and conditions ruled out

Z08

Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85._)

Z12.-

Encounter for screening for malignant neoplasms

Z13.0

Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Z15.0

Genetic susceptibility to malignant neoplasm ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85._)

Z17.0, Z17.1

Estrogen receptor positive and negative status ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50._)

Z40.0-

Encounter for prophylactic surgery for risk factors related to malignant neoplasms

Z42.1

Encounter for breast reconstruction following mastectomy

Z48.290

Encounter for aftercare following bone marrow transplant

Z48.3

Aftercare following surgery for neoplasm ICD-10-CM Coding instruction: Use additional code to identify the neoplasm

Z51.0

Encounter for antineoplastic radiation therapy

Z51.1-

Encounter for antineoplastic chemotherapy and immunotherapy

Z51.5, Z51.89

Encounter for palliative care and other specified aftercare

Z79.81-

Long term (current) use of agents affecting estrogen receptors and estrogen levels ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50._), malignant neoplasm of prostate (C61)

Z80.-

Family history of primary malignant neoplasm

Z85.-

Personal history of malignant neoplasm ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08)

Z86.0-, Z86.01-,

Z86.03

Personal history of in situ and benign neoplasms and neoplasms of uncertain

behavior

Z92.21, Z92.23,

Z92.25, Z92.3

Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)

Z92.850

Personal history of Chimeric Antigen Receptor T-cell therapy- Personal history of CAR-T-cell therapy

Z94.81, Z94.84

Bone marrow and stem cell transplant status